- Home
- BATL vs CTXR Comparison
BATL vs CTXR Comparison
Compare BATL & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BATL | CTXR |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 20.1M |
| IPO Year | 2004 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BATL | CTXR |
|---|---|---|
| Price | $4.13 | $0.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 6.9M | 476.4K |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $193,893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.63 |
| 52 Week High | $6.89 | $2.38 |
Technical Indicators
Market Signals| Indicator | BATL | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 66.72 | 37.72 |
| Support Level | $2.33 | $0.68 |
| Resistance Level | $3.33 | $0.95 |
| Average True Range (ATR) | 0.64 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 59.94 | 4.96 |
Price Performance
Historical ComparisonAbout BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.